Wyeth Pharms patents expiration
1. Duavee patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7138392 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Apr, 2017
(7 years ago) | |
| US5998402 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Apr, 2019
(5 years ago) | |
| US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815934 | WYETH PHARMS | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations |
May, 2019
(4 years ago) | |
| US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(19 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 13, 2018 |
| New Product(NP) | Oct 03, 2016 |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
NCE-1 date: 13 October, 2017
Market Authorisation Date: 03 October, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause; Prevention of postmenopausal osteoporosis
Dosage: TABLET;ORAL
DUAVEE family patents
2. Premphase 14/14 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5547948 | WYETH PHARMS | Controlled release of steroids from sugar coatings |
Jan, 2015
(9 years ago) | |
Drugs and Companies using ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE ingredient
Market Authorisation Date: 04 June, 2003
Treatment: NA
Dosage: TABLET;ORAL-28
PREMPHASE 14/14 family patents
3. Prempro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5547948 | WYETH PHARMS | Controlled release of steroids from sugar coatings |
Jan, 2015
(9 years ago) | |
Drugs and Companies using ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE ingredient
Market Authorisation Date: 04 June, 2003
Treatment: NA
Dosage: TABLET;ORAL-28
PREMPRO family patents
4. Protonix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5997903 | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Dec, 2016
(7 years ago) | |
|
US5997903 (Pediatric) | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Jun, 2017
(6 years ago) | |
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(5 months from now) | |
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(5 months from now) | |
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(5 months from now) | |
|
US7838027 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(11 months from now) | |
|
US7553498 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(11 months from now) | |
|
US7550153 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(11 months from now) | |
| US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(2 years from now) | |
|
US7544370 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 12 June, 2001
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL; TABLET, DELAYED RELEASE;ORAL
PROTONIX family patents
5. Protonix Iv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6780881 | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
Nov, 2021
(2 years ago) | |
| US8754108 | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
Nov, 2021
(2 years ago) | |
| US7351723 | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
Nov, 2021
(2 years ago) | |
|
US8754108 (Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(1 year, 10 months ago) | |
|
US6780881 (Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(1 year, 10 months ago) | |
|
US7351723 (Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(1 year, 10 months ago) | |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 22 March, 2001
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
PROTONIX IV family patents
6. Zosyn patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8133883 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(1 year, 3 days ago) | |
| US7915229 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(1 year, 3 days ago) | |
| US6900184 | WYETH PHARMS | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(1 year, 3 days ago) | |
Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient
Market Authorisation Date: 22 October, 1993
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
ZOSYN family patents